Interestingly, in patients with NSCLC, resistance to receptor tyrosine kinase inhibitor (RTKI) therapy depends on the activation of the EMT program [23] due principally to the release of activated TGFβ, as previously mentioned [24,25]. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.